文献速递妇科

大块型IIIC期卵巢癌、输卵管癌和腹膜癌的最佳初始治疗:初次减灭术达完全肉眼切除还是新辅助化疗是唯一选择?

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
PubMed 文献 · Gynecol Oncol · 2017-02-21

回顾性分析2001年1月至2010年12月在同一机构接受初次减灭术的496例大块型IIIC期卵巢癌、输卵管癌或原发腹膜癌患者,按残留病灶大小分组。中位随访53个月,无肉眼残留组无进展生存期和总生存期最长;残留1-10mm组生存优于残留>10mm组;残留1-10mm且接受静脉/腹腔化疗者总生存期延长。

要点

  • 初次减灭术达无肉眼残留者无进展生存期26.7个月、总生存期83.4个月,均最长。
  • 残留1-10mm者无进展生存期和总生存期优于残留>10mm者。
  • 残留1-10mm且接受静脉/腹腔化疗者较仅静脉化疗者总生存期延长。

核心结论

  • 初次减灭术达无肉眼残留与最长的无进展生存期和总生存期相关。
  • 减灭至残留1-10mm的生存结局也优于残留>10mm。
  • 作者认为初次减灭术对于很可能达到残留1-10mm的患者仍是合适选择,尤其是术后能接受静脉/腹腔化疗的年轻患者。

研究设计与样本

  • 回顾性研究,纳入2001年1月至2010年12月在同一机构接受初次减灭术的大块型IIIC期卵巢癌、输卵管癌或原发腹膜癌患者,排除非上皮性组织学或交界性肿瘤,共496例。
  • 中位年龄62岁,91%为浆液性组织学。
  • 按残留病灶状态分组:无肉眼残留184例(37%)、残留1-5mm 127例(26%)、残留6-10mm 54例(11%)、残留>10mm 131例(26%)。

主要发现

  • 中位随访53个月,四组中位无进展生存期分别为26.7、20.7、16.2和13.6个月(p<0.001)。
  • 四组中位总生存期分别为83.4、54.5、43.8和38.9个月(p<0.001)。
  • 初次减灭术后残留1-10mm者较残留>10mm者无进展生存期改善(p<0.001)、总生存期改善(p=0.001)。
  • 残留1-10mm者中,接受静脉/腹腔化疗者较仅接受静脉化疗者更年轻且总生存期延长(p<0.001和p=0.002)。

临床怎么用

  • 作者认为初次减灭术对于很可能达到残留1-10mm的患者仍是合适选择,尤其是术后能接受静脉/腹腔化疗的年轻患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the impact of primary debulking surgery (PDS) to minimal but gross residual disease (RD) in women with bulky stage IIIC ovarian, fallopian tube, or primary peritoneal cancer. METHODS: We retrospectively reviewed all patients with the aforementioned diagnosis who underwent PDS at our institution from 01/2001-12/2010. Those with disease of non-epithelial histology or borderline tumors were excluded. Clinicopathologic data were abstracted, and appropriate statistical tests were used. RESULTS: We identified 496 eligible patients. Median age was 62years; 91% had disease of serous histology. Patients were grouped by RD status: no gross RD, 184 (37%); RD of 1-5mm, 127 (26%); RD of 6-10mm, 54 (11%); and RD >10mm, 131 (26%). With a median follow-up of 53months, the median progression-free survivals (PFS) were: 26.7, 20.7, 16.2, and 13.6months, respectively (p<0.001). The median overall survivals (OS) were 83.4, 54.5, 43.8, and 38.9months, respectively (p<0.001). Among patients with RD following PDS, those with RD of 1-10mm had improved PFS (p<0.001) and OS (p=0.001) compared with those with RD >10mm. Patients with RD 1-10mm who received intravenous/intraperitoneal (IV/IP) chemotherapy were younger and had prolonged OS compared with those solely exposed to IV chemotherapy (p<0.001 and p=0.002, respectively). CONCLUSIONS: PDS to no gross RD was associated with the longest PFS and OS. However, cytoreduction to 1-10mm of RD was also associated with better survival outcomes compared with cytoreduction to >10mm of RD. We conclude that PDS remains an appropriate option for patients with a high likelihood of achieving RD 1-10mm, especially for younger patients who can receive IV/IP chemotherapy after PDS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sioulas VD, Schiavone MB, Kadouri D, et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol Oncol. 2017. PMID: 28238354. doi:10.1016/j.ygyno.2017.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。